Drugs / KP-001
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06963411 | May → Jul 2025 | anaphylaxis | Kokua Pharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06821698 | Feb → May 2025 | — | Kaken Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT06619054 | Oct 2024 → May 2025 | — | Kaken Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT06649942 | Oct 2024 → Mar 2025 | — | Kaken Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT06227832 | Dec 2023 → Mar 2024 | — | Kaken Pharmaceutical | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07285005 | May 2026 → Feb 2028 expected | CLOVES syndrome, angioosteohypertrophic syndrome, lymphatic malformation, vascular malformation | Kaken Pharmaceutical | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KP001 | “KP-001 therapeutic dose (T): KP-001 100 mg + placebo” NCT06649942 ↗ |
| Action | Inhibit | “KP-001 as an inducer and inhibitor of CYP1A2” NCT06821698 ↗ |
| Route | Oral | “Oral Doses of KP-001” NCT06227832 ↗ |
| Target | CYP1A2 | “KP-001 as an inducer and inhibitor of CYP1A2” NCT06821698 ↗ |